palbociclib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
cyclin dependant kinase inhibitors 4941 571190-30-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • palbociclib
  • palbociclib isethionate
  • ibrance
  • PD-0332991
  • PD-0332991-0054
  • PF-00080665-73
  • PD 0332991
Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reduced cellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression and signaling, and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens led to increased cell senescence compared to each drug alone, which was sustained for up to 6 days following palbociclib removal and was greater if antiestrogen treatment was continued. In vivo studies using a patient-derived ER-positive breast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation, downstream signaling, and tumor growth compared to each drug alone.
  • Molecular weight: 447.54
  • Formula: C24H29N7O2
  • CLOGP: 2.48
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 103.35
  • ALOGS: -4.41
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
94 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 9, 2016 EMA Pfizer Limited
Feb. 3, 2015 FDA PFIZER INC
Sept. 27, 2017 PMDA Pfizer Japan Inc

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neoplasm progression 14159.20 17.16 4594 135097 31834 63317497
White blood cell count decreased 9988.68 17.16 5223 134468 133881 63215450
Fatigue 4972.08 17.16 7726 131965 880302 62469029
Neutropenia 4725.58 17.16 3536 136155 171469 63177862
Full blood count abnormal 1971.14 17.16 1087 138604 30630 63318701
Alopecia 1960.80 17.16 3008 136683 334528 63014803
Neutrophil count decreased 1535.99 17.16 1149 138542 55257 63294074
Full blood count decreased 1305.81 17.16 776 138915 25248 63324083
Nausea 1288.32 17.16 4450 135241 850021 62499310
Hot flush 1227.90 17.16 967 138724 50192 63299139
Stomatitis 1106.91 17.16 1442 138249 137283 63212048
Drug ineffective 1038.51 17.16 506 139185 1044259 62305072
Disease progression 1002.47 17.16 1291 138400 121467 63227864
Red blood cell count decreased 906.26 17.16 736 138955 39909 63309422
Tumour marker increased 860.84 17.16 345 139346 4570 63344761
Decreased appetite 823.23 17.16 1748 137943 249304 63100027
Death 767.13 17.16 2175 137516 372206 62977125
Product dose omission issue 746.72 17.16 1613 138078 232700 63116631
Malignant neoplasm progression 714.76 17.16 892 138799 81229 63268102
Platelet count decreased 589.45 17.16 976 138715 115146 63234185
Constipation 583.20 17.16 1428 138263 223515 63125816
Metastases to bone 575.59 17.16 430 139261 20589 63328742
Dry skin 575.21 17.16 667 139024 56220 63293111
Leukopenia 561.22 17.16 768 138923 76522 63272809
Bone marrow failure 530.88 17.16 471 139220 28819 63320512
Infusion related reaction 512.82 17.16 5 139686 245516 63103815
Bone pain 500.16 17.16 609 139082 54032 63295299
Rheumatoid arthritis 490.27 17.16 15 139676 253804 63095527
Oral pain 479.92 17.16 439 139252 27955 63321376
Diarrhoea 478.95 17.16 2942 136749 712424 62636907
Epistaxis 473.57 17.16 686 139005 72039 63277292
Maternal exposure during pregnancy 452.67 17.16 6 139685 220056 63129275
Contraindicated product administered 451.87 17.16 5 139686 217643 63131688
Systemic lupus erythematosus 416.00 17.16 9 139682 208909 63140422
Second primary malignancy 403.50 17.16 239 139452 7714 63341617
Therapy cessation 366.05 17.16 391 139300 30066 63319265
Therapeutic product effect decreased 353.93 17.16 17 139674 193170 63156161
Asthenia 342.69 17.16 1708 137983 381896 62967435
Drug hypersensitivity 342.25 17.16 128 139563 310559 63038772
Toxicity to various agents 335.42 17.16 68 139623 247182 63102149
Hand deformity 333.99 17.16 3 139688 159454 63189877
Metastases to liver 333.86 17.16 331 139360 23308 63326023
Arthropathy 326.02 17.16 61 139630 234731 63114600
Product dose omission in error 322.84 17.16 204 139487 7408 63341923
Joint swelling 316.71 17.16 163 139528 327503 63021828
Treatment failure 312.57 17.16 36 139655 199007 63150324
Completed suicide 303.86 17.16 3 139688 145670 63203661
Swelling 289.21 17.16 122 139569 275256 63074075
Thrombocytopenia 269.92 17.16 838 138853 150319 63199012
Pericarditis 264.50 17.16 5 139686 131574 63217757
Drug intolerance 263.68 17.16 178 139513 308483 63040848
Neuropathy peripheral 247.93 17.16 677 139014 112990 63236341
Hypersensitivity 235.30 17.16 180 139511 292505 63056826
Wound 233.99 17.16 39 139652 163224 63186107
Breast cancer metastatic 231.22 17.16 200 139491 11818 63337513
Taste disorder 211.09 17.16 201 139490 13461 63335870
Hypotension 206.20 17.16 178 139513 272426 63076905
White blood cell count abnormal 201.17 17.16 141 139550 6101 63343230
Lower respiratory tract infection 190.92 17.16 31 139660 132276 63217055
Intentional product use issue 189.01 17.16 28 139663 127864 63221467
Dysgeusia 188.06 17.16 355 139336 46355 63302976
Psoriatic arthropathy 185.89 17.16 3 139688 91517 63257814
Acute kidney injury 185.02 17.16 184 139507 263231 63086100
Cytopenia 179.84 17.16 171 139520 11430 63337901
Blood test abnormal 179.60 17.16 196 139495 15433 63333898
Onychoclasis 178.61 17.16 131 139560 6091 63343240
Carbohydrate antigen 15-3 increased 177.85 17.16 79 139612 1369 63347962
Discomfort 175.82 17.16 74 139617 167300 63182031
Therapy change 165.52 17.16 124 139567 5957 63343374
Lacrimation increased 161.78 17.16 213 139478 20418 63328913
Injection site pain 161.39 17.16 43 139648 129757 63219574
Asthma 157.20 17.16 43 139648 127518 63221813
Laboratory test abnormal 156.61 17.16 241 139450 26671 63322660
Therapeutic product effect incomplete 148.86 17.16 45 139646 125011 63224320
COVID-19 145.85 17.16 563 139128 112540 63236791
Injection site erythema 144.04 17.16 10 139681 83164 63266167
Overdose 141.41 17.16 39 139652 115039 63234292
Anaemia 136.28 17.16 1107 138584 292323 63057008
Tachycardia 136.21 17.16 45 139646 118111 63231220
Glossodynia 136.13 17.16 116 139575 178760 63170571
Haemoglobin decreased 134.48 17.16 655 139036 144830 63204501
Musculoskeletal stiffness 134.17 17.16 125 139566 184493 63164838
Irritable bowel syndrome 134.17 17.16 13 139678 82399 63266932
PIK3CA-activated mutation 134.01 17.16 59 139632 1000 63348331
Ill-defined disorder 132.83 17.16 13 139678 81742 63267589
Hypertension 128.77 17.16 263 139428 279040 63070291
Osteonecrosis of jaw 126.82 17.16 255 139436 34868 63314463
Mobility decreased 121.81 17.16 57 139634 121102 63228229
Fibromyalgia 120.21 17.16 17 139674 80403 63268928
Cancer pain 118.95 17.16 79 139612 3126 63346205
Madarosis 116.91 17.16 77 139614 3004 63346327
Suicide attempt 116.05 17.16 4 139687 60914 63288417
Cough 111.78 17.16 1058 138633 291685 63057646
Ageusia 111.15 17.16 144 139547 13584 63335747
Hepatic enzyme increased 109.87 17.16 172 139519 202156 63147175
Psoriasis 109.61 17.16 28 139663 86929 63262402
White blood cell disorder 107.67 17.16 68 139623 2466 63346865
Sinusitis 106.50 17.16 211 139480 226442 63122889
Injury 106.00 17.16 17 139674 73230 63276101
Blood cholesterol increased 101.26 17.16 40 139651 93992 63255339
Condition aggravated 100.03 17.16 500 139191 401717 62947614
Adverse event 99.31 17.16 15 139676 67544 63281787
Type 2 diabetes mellitus 99.06 17.16 12 139679 63856 63285475
Confusional state 98.70 17.16 235 139456 236145 63113186
Fall 98.55 17.16 486 139205 391848 62957483
Breast pain 97.04 17.16 108 139583 8690 63340641
Cardiac arrest 97.01 17.16 41 139650 92504 63256827
Myelosuppression 96.44 17.16 181 139510 23522 63325809
Bradycardia 95.38 17.16 22 139669 73205 63276126
Lymphoedema 93.66 17.16 122 139569 11570 63337761
Cardio-respiratory arrest 93.65 17.16 11 139680 59948 63289383
Decreased immune responsiveness 93.13 17.16 81 139610 4820 63344511
Coma 90.78 17.16 16 139675 64348 63284983
Injection site reaction 90.76 17.16 11 139680 58513 63290818
Illness 90.22 17.16 275 139416 48784 63300547
Osteoarthritis 89.61 17.16 49 139642 95294 63254037
Adverse drug reaction 89.02 17.16 32 139659 79682 63269649
Drug interaction 88.51 17.16 237 139454 228894 63120437
Metastases to lung 88.37 17.16 124 139567 12626 63336705
Urticaria 88.06 17.16 143 139548 165659 63183672
Back pain 87.89 17.16 928 138763 263217 63086114
Anaphylactic reaction 87.82 17.16 19 139672 66081 63283250
Oral mucosal blistering 86.01 17.16 83 139608 5650 63343681
Seizure 85.94 17.16 99 139592 132535 63216796
Neoplasm recurrence 83.63 17.16 59 139632 2579 63346752
Medication error 83.15 17.16 9 139682 52275 63297056
Wheezing 83.00 17.16 54 139637 95541 63253790
Metabolic acidosis 82.35 17.16 4 139687 45065 63304266
C-reactive protein increased 81.54 17.16 54 139637 94653 63254678
Hepatic lesion 80.32 17.16 74 139617 4751 63344580
Knee arthroplasty 79.75 17.16 12 139679 54194 63295137
Immune system disorder 79.37 17.16 103 139588 9731 63339600
Injection site pruritus 79.36 17.16 5 139686 45111 63304220
Nail disorder 79.18 17.16 119 139572 12896 63336435
Suicidal ideation 76.95 17.16 21 139670 62400 63286931
Off label use 76.41 17.16 1036 138655 673426 62675905
Depressed level of consciousness 76.31 17.16 21 139670 62057 63287274
Flatulence 75.87 17.16 207 139484 34495 63314836
Syncope 75.63 17.16 88 139603 117297 63232034
Oxygen saturation decreased 71.67 17.16 54 139637 88531 63260800
Respiratory failure 71.58 17.16 71 139620 101787 63247544
Hyponatraemia 70.90 17.16 85 139606 111815 63237516
Nasal dryness 70.00 17.16 67 139624 4514 63344817
Gingival pain 69.83 17.16 88 139603 8074 63341257
Body surface area increased 69.49 17.16 17 139674 31 63349300
Incorrect dose administered 67.08 17.16 24 139667 59944 63289387
Sedation 66.22 17.16 5 139686 38804 63310527
Pleural effusion 65.87 17.16 390 139301 92820 63256511
Blood pressure increased 65.33 17.16 164 139527 161898 63187433
Memory impairment 64.76 17.16 422 139269 103836 63245495
Hip arthroplasty 64.73 17.16 13 139678 47633 63301698
Hypoglycaemia 63.92 17.16 26 139665 60039 63289292
Gastrointestinal haemorrhage 63.74 17.16 51 139640 81125 63268206
Tumour marker abnormal 63.74 17.16 26 139665 361 63348970
Therapeutic response decreased 63.29 17.16 28 139663 61497 63287834
Plasma cell myeloma 63.09 17.16 4 139687 35901 63313430
Flushing 63.05 17.16 44 139647 75043 63274288
Gastrointestinal disorder 62.61 17.16 121 139570 131118 63218213
Bursitis 62.56 17.16 5 139686 37036 63312295
Cardiac failure congestive 62.05 17.16 67 139624 92366 63256965
Oedema peripheral 61.72 17.16 212 139479 189299 63160032
Multiple organ dysfunction syndrome 61.32 17.16 24 139667 56728 63292603
Blood pressure systolic increased 60.23 17.16 15 139676 47382 63301949
Product quality issue 60.14 17.16 5 139686 35860 63313471
Carbohydrate antigen 27.29 increased 59.62 17.16 16 139675 49 63349282
Angioedema 59.38 17.16 16 139675 47949 63301382
Respiratory arrest 59.32 17.16 3 139688 32642 63316689
Injection site swelling 58.65 17.16 16 139675 47556 63301775
Pneumonia 58.57 17.16 683 139008 456084 62893247
Pancytopenia 58.17 17.16 389 139302 96544 63252787
Oedema 57.85 17.16 78 139613 97544 63251787
Septic shock 57.34 17.16 38 139653 66591 63282740
Liver injury 57.01 17.16 31 139660 60489 63288842
Encephalopathy 55.79 17.16 9 139682 38611 63310720
Musculoskeletal chest pain 55.63 17.16 135 139556 20948 63328383
Hypokalaemia 55.59 17.16 89 139602 103715 63245616
Hair texture abnormal 55.47 17.16 57 139634 4186 63345145
Pulmonary hypertension 55.11 17.16 8 139683 37115 63312216
Erythema 54.30 17.16 201 139490 175550 63173781
Hypoacusis 53.73 17.16 145 139546 24006 63325325
Inflammation 52.64 17.16 62 139629 82211 63267120
Skin exfoliation 52.63 17.16 211 139480 42891 63306440
Inappropriate schedule of product administration 52.11 17.16 93 139598 103872 63245459
Metastases to pleura 51.53 17.16 36 139655 1549 63347782
Body surface area decreased 51.33 17.16 12 139679 16 63349315
Palpitations 51.20 17.16 107 139584 112663 63236668
Lactic acidosis 50.87 17.16 11 139680 38276 63311055
Obesity 50.71 17.16 4 139687 29948 63319383
Coronary artery disease 50.41 17.16 6 139685 32371 63316960
Loss of consciousness 50.39 17.16 116 139575 118005 63231326
Unevaluable event 50.36 17.16 25 139666 51361 63297970
Impaired healing 50.26 17.16 93 139598 102449 63246882
Prescribed underdose 50.16 17.16 4 139687 29685 63319646
Injection site bruising 49.99 17.16 15 139676 41895 63307436
Dizziness 49.86 17.16 1268 138423 428657 62920674
International normalised ratio increased 49.56 17.16 20 139671 46405 63302926
Blister 49.54 17.16 135 139556 129679 63219652
Prescribed overdose 49.24 17.16 8 139683 34145 63315186
Haematotoxicity 49.07 17.16 80 139611 9296 63340035
Delirium 48.92 17.16 25 139666 50516 63298815
Rhinorrhoea 48.67 17.16 278 139413 65299 63284032
Unresponsive to stimuli 48.58 17.16 8 139683 33808 63315523
Dyspepsia 47.54 17.16 386 139305 101810 63247521
Malignant pleural effusion 47.37 17.16 42 139649 2564 63346767
Metastases to lymph nodes 47.37 17.16 73 139618 8085 63341246
Orthostatic hypotension 46.81 17.16 11 139680 36149 63313182
Metastases to spine 46.79 17.16 46 139645 3203 63346128
Foot deformity 46.38 17.16 4 139687 27849 63321482
Sleep apnoea syndrome 46.36 17.16 5 139686 29128 63320203
Dysarthria 46.25 17.16 18 139673 42693 63306638
Abdominal pain 46.11 17.16 418 139273 293038 63056293
Pneumonia aspiration 45.73 17.16 10 139681 34530 63314801
Dry mouth 45.23 17.16 310 139381 77553 63271778
Pulmonary thrombosis 45.20 17.16 74 139617 8628 63340703
Hyperkalaemia 45.19 17.16 32 139659 54171 63295160
Agitation 45.11 17.16 39 139652 59718 63289613
Drug withdrawal syndrome 45.02 17.16 4 139687 27190 63322141
Psychotic disorder 44.77 17.16 3 139688 25709 63323622
Metastases to kidney 44.06 17.16 17 139674 202 63349129
Feeling cold 43.99 17.16 134 139557 23754 63325577
Heart rate increased 43.98 17.16 88 139603 94150 63255181
Ascites 43.96 17.16 192 139499 40536 63308795
Altered state of consciousness 43.77 17.16 3 139688 25227 63324104
Neutrophil count abnormal 43.63 17.16 42 139649 2850 63346481
Hallucination 43.59 17.16 34 139657 54783 63294548
Nail growth abnormal 43.21 17.16 22 139669 523 63348808
Oropharyngeal pain 42.93 17.16 355 139336 94132 63255199
Atrial fibrillation 42.50 17.16 124 139567 116512 63232819
Leukocytosis 42.44 17.16 4 139687 25931 63323400
Weight increased 42.05 17.16 369 139322 260423 63088908
Heart rate decreased 41.96 17.16 24 139667 45536 63303795
Injection site haemorrhage 41.86 17.16 3 139688 24311 63325020
Haematuria 41.66 17.16 7 139684 29150 63320181
Carcinoembryonic antigen increased 41.50 17.16 33 139658 1732 63347599
Angina pectoris 41.29 17.16 8 139683 30070 63319261
Spinal pain 41.13 17.16 90 139601 13049 63336282
Pneumonitis 41.07 17.16 170 139521 35052 63314279
Product dispensing error 41.05 17.16 78 139613 10227 63339104
Hair growth abnormal 40.71 17.16 41 139650 2940 63346391
Therapy non-responder 40.70 17.16 65 139626 75836 63273495
Blood pressure fluctuation 40.41 17.16 26 139665 46291 63303040
Appetite disorder 40.41 17.16 64 139627 7257 63342074
Emotional distress 40.02 17.16 11 139680 32538 63316793
Blood creatine phosphokinase increased 39.90 17.16 9 139682 30421 63318910
Product packaging difficult to open 39.87 17.16 13 139678 90 63349241
Pancreatitis 39.55 17.16 30 139661 49025 63300306
Drug dependence 39.48 17.16 4 139687 24479 63324852
Drug ineffective for unapproved indication 39.19 17.16 13 139678 34050 63315281
Eating disorder 38.19 17.16 110 139581 18906 63330425
Pseudocirrhosis 37.84 17.16 22 139669 685 63348646
Metastases to retroperitoneum 37.58 17.16 14 139677 150 63349181
Vomiting 37.53 17.16 1546 138145 558071 62791260
Aggression 37.47 17.16 4 139687 23494 63325837
Breast cancer recurrent 37.45 17.16 47 139644 4294 63345037
Acute myocardial infarction 37.41 17.16 12 139679 32112 63317219
Myocardial infarction 37.27 17.16 105 139586 99788 63249543
Respiratory distress 37.27 17.16 14 139677 33937 63315394
Dysphagia 36.65 17.16 326 139365 88259 63261072
Body temperature increased 36.59 17.16 18 139673 37174 63312157
Joint range of motion decreased 36.23 17.16 13 139678 32415 63316916
Hypoxia 36.21 17.16 47 139644 59745 63289586
Tremor 35.94 17.16 159 139532 132080 63217251
Blood pressure diastolic decreased 35.87 17.16 4 139687 22702 63326629
Stevens-Johnson syndrome 35.62 17.16 6 139685 24944 63324387
Mucosal inflammation 35.51 17.16 200 139491 46728 63302603
Basal cell carcinoma 35.29 17.16 9 139682 27982 63321349
Rash maculo-papular 35.27 17.16 13 139678 31883 63317448
Grip strength decreased 35.02 17.16 4 139687 22283 63327048
Cytomegalovirus infection 34.91 17.16 3 139688 20949 63328382
Chest pain 34.60 17.16 306 139385 215653 63133678
Infection 34.44 17.16 330 139361 228843 63120488
Dry eye 34.42 17.16 179 139512 40582 63308749
Bone cancer 33.99 17.16 27 139664 1415 63347916
Dyskinesia 33.81 17.16 14 139677 31988 63317343
Faeces soft 33.14 17.16 51 139640 5641 63343690
Granulocyte count decreased 33.11 17.16 25 139666 1215 63348116
Anaphylactic shock 33.05 17.16 6 139685 23627 63325704
Wrong technique in product usage process 32.85 17.16 54 139637 62286 63287045
Nasal discomfort 32.55 17.16 46 139645 4714 63344617
Mental status changes 32.20 17.16 24 139667 39575 63309756
Sinus tachycardia 32.18 17.16 7 139684 24261 63325070
Mitral valve incompetence 32.12 17.16 3 139688 19591 63329740
Thrombosis 31.97 17.16 248 139443 64507 63284824
Weight decreased 31.91 17.16 816 138875 275982 63073349
Hypomagnesaemia 31.30 17.16 12 139679 28725 63320606
Proteinuria 31.20 17.16 3 139688 19142 63330189
Adnexa uteri mass 31.12 17.16 18 139673 555 63348776
Metastases to skin 30.62 17.16 27 139664 1636 63347695
Joint dislocation 30.50 17.16 3 139688 18797 63330534
Ventricular tachycardia 30.38 17.16 4 139687 19975 63329356
Hemiparesis 30.30 17.16 7 139684 23275 63326056
Hair disorder 30.30 17.16 23 139668 1127 63348204
Metastases to bladder 30.15 17.16 13 139678 209 63349122
Pallor 29.76 17.16 15 139676 30553 63318778
Diabetic ketoacidosis 29.12 17.16 5 139686 20500 63328831
Incorrect route of product administration 29.02 17.16 12 139679 27440 63321891
Cardiac failure 28.80 17.16 100 139591 89042 63260289
Staphylococcal infection 28.70 17.16 29 139662 41227 63308104
Adrenal insufficiency 28.70 17.16 3 139688 17912 63331419
Hypercholesterolaemia 28.60 17.16 6 139685 21328 63328003
Multiple sclerosis 28.57 17.16 9 139682 24363 63324968
Haematoma 28.44 17.16 21 139670 34799 63314532
Loss of personal independence in daily activities 28.27 17.16 114 139577 97176 63252155
General physical health deterioration 28.18 17.16 295 139396 201107 63148224
Trichorrhexis 27.98 17.16 23 139668 1266 63348065
Tachypnoea 27.45 17.16 3 139688 17299 63332032
Obstructive airways disorder 27.39 17.16 6 139685 20693 63328638
Drug level increased 27.37 17.16 8 139683 22728 63326603
Insomnia 27.32 17.16 643 139048 214609 63134722
Chronic kidney disease 27.16 17.16 36 139655 45362 63303969
Vasculitis 26.85 17.16 4 139687 18205 63331126
Red blood cell count abnormal 26.73 17.16 21 139670 1083 63348248
Melaena 26.55 17.16 17 139674 30348 63318983
Arrhythmia 26.31 17.16 27 139664 38113 63311218
Urine odour abnormal 26.25 17.16 49 139642 6340 63342991
Device malfunction 26.16 17.16 4 139687 17853 63331478
Hypervolaemia 26.11 17.16 15 139676 28398 63320933
Parosmia 26.00 17.16 48 139643 6158 63343173
Toothache 25.89 17.16 97 139594 19102 63330229
Injection site rash 25.82 17.16 5 139686 18804 63330527
Increased appetite 25.76 17.16 62 139629 9568 63339763
Swelling face 25.74 17.16 64 139627 63411 63285920
Aphthous ulcer 25.49 17.16 78 139613 13860 63335471
Radiation injury 25.43 17.16 15 139676 480 63348851
Poor quality product administered 25.38 17.16 33 139658 3123 63346208
Drug eruption 25.18 17.16 16 139675 28678 63320653
Arthritis 24.94 17.16 151 139540 115770 63233561
Prehypertension 24.65 17.16 7 139684 28 63349303
Joint effusion 24.58 17.16 4 139687 17056 63332275
Cardiogenic shock 24.13 17.16 5 139686 17927 63331404
Metastasis 24.08 17.16 42 139649 5155 63344176
Skin ulcer 23.90 17.16 36 139655 43009 63306322
Eructation 23.76 17.16 55 139636 8278 63341053
Night sweats 23.57 17.16 186 139505 48628 63300703
Muscle twitching 23.53 17.16 7 139684 19661 63329670
Abnormal behaviour 23.24 17.16 9 139682 21417 63327914
Osteoporosis 23.10 17.16 58 139633 57280 63292051
Treatment noncompliance 22.95 17.16 29 139662 37296 63312035
No adverse event 22.63 17.16 35 139656 41370 63307961
Chronic obstructive pulmonary disease 22.57 17.16 67 139624 62619 63286712
Transient ischaemic attack 22.52 17.16 30 139661 37723 63311608
Ovarian cyst 22.40 17.16 4 139687 15941 63333390
Ovarian disorder 22.39 17.16 16 139675 714 63348617
Foreign body in throat 22.39 17.16 12 139679 318 63349013
Macular degeneration 22.22 17.16 13 139678 24363 63324968
Shock 22.12 17.16 12 139679 23451 63325880
Pulmonary arterial hypertension 22.10 17.16 11 139680 22566 63326765
Upper gastrointestinal haemorrhage 22.03 17.16 7 139684 18845 63330486
Intervertebral disc degeneration 21.99 17.16 4 139687 15728 63333603
Myalgia 21.85 17.16 448 139243 146081 63203250
Metastases to adrenals 21.71 17.16 16 139675 749 63348582
Metastases to peritoneum 21.69 17.16 32 139659 3410 63345921
Coagulopathy 21.68 17.16 9 139682 20535 63328796
Tendonitis 21.68 17.16 8 139683 19607 63329724
Ear infection 21.18 17.16 32 139659 38181 63311150
Lip pain 21.15 17.16 23 139668 1803 63347528
Lupus-like syndrome 21.14 17.16 4 139687 15291 63334040
Pleural neoplasm 21.07 17.16 12 139679 359 63348972
Arthralgia 21.06 17.16 1489 138202 568221 62781110
Circulatory collapse 21.01 17.16 11 139680 21927 63327404
Road traffic accident 20.96 17.16 30 139661 36602 63312729
Infusion site coldness 20.94 17.16 10 139681 206 63349125
Hypersomnia 20.93 17.16 87 139604 17968 63331363
Mean cell volume increased 20.93 17.16 32 139659 3519 63345812
Acute respiratory distress syndrome 20.82 17.16 13 139678 23521 63325810
Autoimmune disorder 20.76 17.16 6 139685 17171 63332160
Artificial menopause 20.74 17.16 6 139685 26 63349305
Hypothyroidism 20.59 17.16 39 139652 42593 63306738
Eastern Cooperative Oncology Group performance status worsened 20.42 17.16 19 139672 1235 63348096
Respiratory depression 20.25 17.16 3 139688 13712 63335619
Exostosis 20.23 17.16 7 139684 17855 63331476
Feeding disorder 20.13 17.16 70 139621 13292 63336039
Tongue blistering 20.08 17.16 21 139670 1574 63347757
Tumour pain 20.06 17.16 20 139671 1417 63347914
Neuroendocrine breast tumour 20.04 17.16 6 139685 30 63349301
Noninfective gingivitis 20.01 17.16 20 139671 1421 63347910
Liver function test abnormal 19.99 17.16 48 139643 48133 63301198
Tongue discomfort 19.97 17.16 25 139666 2278 63347053
Sepsis 19.92 17.16 228 139463 152895 63196436
Pain 19.89 17.16 1383 138308 739245 62610086
Gingival bleeding 19.89 17.16 67 139624 12520 63336811
Joint neoplasm 19.87 17.16 7 139684 63 63349268
Hepatitis 19.56 17.16 36 139655 39752 63309579
Peripheral venous disease 19.46 17.16 5 139686 15472 63333859
Hypogeusia 19.46 17.16 19 139672 1312 63348019
Underdose 19.44 17.16 19 139672 27437 63321894
Hypoaesthesia 19.25 17.16 496 139195 167897 63181434
Bronchospasm 19.18 17.16 7 139684 17273 63332058
Hypertensive crisis 19.11 17.16 5 139686 15281 63334050
Soft tissue neoplasm 19.04 17.16 7 139684 72 63349259
Feeling abnormal 19.03 17.16 444 139247 147948 63201383
Pyrexia 18.98 17.16 844 138847 469634 62879697
Product substitution issue 18.58 17.16 6 139685 15990 63333341
Myocardial ischaemia 18.56 17.16 3 139688 12856 63336475
Cyanosis 18.56 17.16 7 139684 16928 63332403
Product use complaint 18.56 17.16 25 139666 2449 63346882
Migraine 18.56 17.16 142 139549 103204 63246127
Osteonecrosis 18.52 17.16 16 139675 24514 63324817
Blood pressure decreased 18.38 17.16 77 139614 64945 63284386
Tongue disorder 18.23 17.16 58 139633 10522 63338809
Urinary retention 18.16 17.16 24 139667 30277 63319054
Face oedema 18.11 17.16 11 139680 20201 63329130
Dental discomfort 18.11 17.16 12 139679 473 63348858
Acute respiratory failure 18.05 17.16 30 139661 34455 63314876
Metastases to the mediastinum 18.04 17.16 12 139679 476 63348855
Hallucination, visual 18.00 17.16 10 139681 19288 63330043
Uveitis 17.96 17.16 3 139688 12550 63336781
Nail discolouration 17.96 17.16 26 139665 2724 63346607
Mastectomy 17.93 17.16 20 139671 1613 63347718
Acute cutaneous lupus erythematosus 17.84 17.16 10 139681 290 63349041
Femur fracture 17.80 17.16 41 139650 41715 63307616
Breast cancer female 17.80 17.16 4 139687 13555 63335776
Mania 17.60 17.16 3 139688 12364 63336967
Haemorrhage intracranial 17.53 17.16 4 139687 13415 63335916
Skin sensitisation 17.51 17.16 15 139676 874 63348457
Clostridium difficile colitis 17.33 17.16 12 139679 20557 63328774
Cholelithiasis 17.26 17.16 45 139646 43880 63305451
Gamma-glutamyltransferase decreased 17.24 17.16 10 139681 310 63349021
Product packaging issue 17.23 17.16 17 139674 1189 63348142
Spinal osteoarthritis 17.23 17.16 7 139684 16179 63333152

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use issue 537.45 32.45 199 2687 63017 34891028
Neoplasm progression 487.30 32.45 145 2741 23155 34930890
Fatigue 145.10 32.45 164 2722 370489 34583556
Product use in unapproved indication 139.72 32.45 98 2788 117401 34836644
Off label use 127.04 32.45 163 2723 419361 34534684
White blood cell count decreased 111.87 32.45 79 2807 95366 34858679
Hydrocephalus 57.20 32.45 20 2866 5212 34948833
Neutropenia 53.32 32.45 65 2821 156713 34797332
Hot flush 52.80 32.45 27 2859 18039 34936006
Death 50.75 32.45 105 2781 397944 34556101
Xerosis 43.08 32.45 10 2876 594 34953451

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neoplasm progression 13134.13 17.99 4408 127345 47274 79565361
White blood cell count decreased 9566.54 17.99 5101 126652 183187 79429448
Fatigue 6116.32 17.99 7530 124223 922197 78690438
Alopecia 3346.35 17.99 2882 128871 228473 79384162
Neutropenia 3064.02 17.99 3020 128733 284690 79327945
Full blood count abnormal 1931.37 17.99 1057 130696 39417 79573218
Nausea 1592.83 17.99 4282 127471 952914 78659721
Full blood count decreased 1398.04 17.99 743 131010 26076 79586559
Hot flush 1391.80 17.99 957 130796 53920 79558715
Stomatitis 1265.42 17.99 1379 130374 145378 79467257
Neutrophil count decreased 1202.74 17.99 1095 130658 92864 79519771
Product dose omission issue 1007.96 17.99 1608 130145 245929 79366706
Tumour marker increased 888.91 17.99 315 131438 3957 79608678
Red blood cell count decreased 838.67 17.99 722 131031 56791 79555844
Drug ineffective 811.49 17.99 389 131364 1080524 78532111
Decreased appetite 760.02 17.99 1717 130036 340701 79271934
Dry skin 616.83 17.99 657 131096 67338 79545297
Constipation 607.18 17.99 1401 130352 281649 79330986
Disease progression 598.96 17.99 1084 130669 183278 79429357
Bone pain 549.22 17.99 563 131190 55179 79557456
Oral pain 541.85 17.99 437 131316 31361 79581274
Diarrhoea 515.93 17.99 2831 128922 877658 78734977
Toxicity to various agents 483.61 17.99 63 131690 421477 79191158
Death 416.01 17.99 1943 129810 564571 79048064
Acute kidney injury 413.11 17.99 171 131582 519233 79093402
Platelet count decreased 409.70 17.99 957 130796 193707 79418928
Epistaxis 385.31 17.99 674 131079 110841 79501794
Product dose omission in error 383.85 17.99 208 131545 7580 79605055
Infusion related reaction 354.27 17.99 5 131748 230232 79382403
Leukopenia 346.54 17.99 660 131093 115853 79496782
Bone marrow failure 345.09 17.99 424 131329 50683 79561952
Metastases to bone 326.46 17.99 292 131461 24135 79588500
Asthenia 319.01 17.99 1676 130077 510013 79102622
Second primary malignancy 302.92 17.99 224 131529 14126 79598509
Hypotension 294.44 17.99 182 131571 440135 79172500
Rheumatoid arthritis 289.25 17.99 13 131740 208457 79404178
Therapy cessation 287.11 17.99 332 131421 37230 79575405
Drug hypersensitivity 236.35 17.99 99 131654 298817 79313818
Contraindicated product administered 235.77 17.99 5 131748 157533 79455102
White blood cell count abnormal 235.62 17.99 136 131617 5609 79607026
Neuropathy peripheral 230.46 17.99 631 131122 140674 79471961
Taste disorder 229.15 17.99 198 131555 15625 79597010
Therapeutic product effect decreased 218.52 17.99 13 131740 163850 79448785
Drug interaction 216.61 17.99 220 131533 414963 79197672
Onychoclasis 215.42 17.99 127 131626 5451 79607184
Maternal exposure during pregnancy 209.82 17.99 3 131750 136535 79476100
Dysgeusia 209.70 17.99 355 131398 56822 79555813
Laboratory test abnormal 206.15 17.99 243 131510 27805 79584830
Blood test abnormal 200.45 17.99 193 131560 17517 79595118
Lacrimation increased 199.81 17.99 215 131538 22262 79590373
Overdose 198.31 17.99 33 131720 184173 79428462
Carbohydrate antigen 15-3 increased 186.28 17.99 71 131682 1108 79611527
Treatment failure 178.15 17.99 33 131720 170453 79442182
Tachycardia 174.20 17.99 40 131713 177728 79434907
Cardiac arrest 174.17 17.99 36 131717 172060 79440575
Intentional product use issue 173.52 17.99 23 131730 152089 79460546
Systemic lupus erythematosus 173.26 17.99 6 131747 121143 79491492
Metastases to liver 169.04 17.99 221 131532 28093 79584542
Breast cancer metastatic 165.40 17.99 127 131626 8475 79604160
Hand deformity 156.66 17.99 3 131750 103916 79508719
Malignant neoplasm progression 152.47 17.99 533 131220 135457 79477178
Pericarditis 149.63 17.99 5 131748 104231 79508404
Drug intolerance 148.10 17.99 131 131622 263988 79348647
Illness 147.54 17.99 271 131482 46240 79566395
Joint swelling 144.74 17.99 158 131595 288488 79324147
Bradycardia 144.30 17.99 25 131728 135532 79477103
Therapy change 139.56 17.99 108 131645 7291 79605344
Cardio-respiratory arrest 137.69 17.99 11 131742 108499 79504136
Arthropathy 134.62 17.99 62 131691 177049 79435586
Respiratory failure 133.42 17.99 66 131687 180845 79431790
Gastrointestinal haemorrhage 131.88 17.99 40 131713 147679 79464956
Madarosis 127.49 17.99 71 131682 2731 79609904
Multiple organ dysfunction syndrome 126.20 17.99 23 131730 120223 79492412
COVID-19 124.09 17.99 553 131200 157121 79455514
Therapeutic product effect incomplete 123.51 17.99 40 131713 141605 79471030
Back pain 123.50 17.99 893 130860 303287 79309348
Cough 122.50 17.99 1029 130724 365760 79246875
Metabolic acidosis 121.97 17.99 3 131750 82526 79530109
Pneumonia 116.91 17.99 628 131125 659618 78953017
Breast pain 116.79 17.99 102 131651 8163 79604472
Suicide attempt 115.53 17.99 5 131748 82927 79529708
Psoriatic arthropathy 114.65 17.99 3 131750 77996 79534639
Lymphoedema 114.32 17.99 121 131632 12292 79600343
Asthma 112.85 17.99 41 131712 135054 79477581
Hypersensitivity 112.18 17.99 162 131591 262077 79350558
Lower respiratory tract infection 111.77 17.99 37 131716 129183 79483452
Injection site pain 110.87 17.99 38 131715 129800 79482835
Product use issue 110.71 17.99 658 131095 209164 79403471
Ageusia 110.62 17.99 137 131616 16495 79596140
Coma 110.61 17.99 17 131736 100632 79512003
Arthralgia 109.67 17.99 1433 130320 570370 79042265
Hyperkalaemia 109.57 17.99 27 131726 114371 79498264
Memory impairment 108.43 17.99 418 131335 111316 79501319
Decreased immune responsiveness 107.83 17.99 82 131671 5393 79607242
Hyponatraemia 107.35 17.99 82 131671 177766 79434869
Depressed level of consciousness 106.96 17.99 16 131737 96636 79515999
Seizure 106.61 17.99 93 131660 188741 79423894
Septic shock 106.49 17.99 35 131718 122766 79489869
Hypertension 106.30 17.99 244 131509 330748 79281887
Confusional state 105.73 17.99 230 131523 317767 79294868
Syncope 105.46 17.99 85 131668 179364 79433271
Swelling 103.84 17.99 123 131630 216588 79396047
White blood cell disorder 103.54 17.99 65 131688 3127 79609508
Nail disorder 101.19 17.99 111 131642 11741 79600894
Oral mucosal blistering 96.18 17.99 81 131672 6170 79606465
Hypoglycaemia 95.33 17.99 25 131728 101569 79511066
Atrial fibrillation 94.07 17.99 113 131640 197773 79414862
C-reactive protein increased 93.72 17.99 48 131705 128979 79483656
Injection site erythema 93.66 17.99 10 131743 78187 79534448
Cytopenia 93.20 17.99 140 131613 20243 79592392
Wound 92.49 17.99 38 131715 116141 79496494
Cardiac failure congestive 92.05 17.99 61 131692 142341 79470294
Cancer pain 91.25 17.99 73 131680 5172 79607463
Fall 91.16 17.99 455 131298 487174 79125461
Oxygen saturation decreased 87.94 17.99 52 131701 128995 79483640
Condition aggravated 87.28 17.99 479 131274 500645 79111990
Blood pressure systolic increased 87.23 17.99 6 131747 66980 79545655
Acute myocardial infarction 86.99 17.99 12 131741 77024 79535611
Myocardial infarction 86.61 17.99 106 131647 184023 79428612
Haemoglobin decreased 86.02 17.99 645 131108 221474 79391161
Dyspepsia 85.32 17.99 381 131372 108306 79504329
International normalised ratio increased 85.11 17.99 18 131735 84703 79527932
Flatulence 84.22 17.99 205 131548 42519 79570116
Anaphylactic reaction 83.70 17.99 18 131735 83725 79528910
Angioedema 83.18 17.99 13 131740 76022 79536613
Delirium 82.95 17.99 19 131734 84608 79528027
Thrombocytopenia 82.08 17.99 732 131021 264527 79348108
Coronary artery disease 82.05 17.99 7 131746 65467 79547168
Lactic acidosis 81.76 17.99 10 131743 70349 79542286
Respiratory arrest 81.75 17.99 3 131750 57547 79555088
Medication error 81.65 17.99 9 131744 68633 79544002
Nasal dryness 80.43 17.99 64 131689 4499 79608136
Sepsis 79.87 17.99 207 131546 269221 79343414
Gingival pain 79.84 17.99 86 131667 8912 79603723
Haematuria 79.46 17.99 10 131743 68826 79543809
Injury 78.81 17.99 16 131737 77480 79535155
Cardiac failure 78.39 17.99 84 131669 154758 79457877
Osteonecrosis of jaw 77.44 17.99 200 131553 43026 79569609
Encephalopathy 77.29 17.99 10 131743 67387 79545248
Psoriasis 76.85 17.99 26 131727 89561 79523074
Pneumonia aspiration 76.64 17.99 10 131743 66957 79545678
Oedema peripheral 75.41 17.99 193 131560 252095 79360540
Hair texture abnormal 74.20 17.99 55 131698 3479 79609156
Mobility decreased 74.13 17.99 56 131697 122119 79490516
Immune system disorder 73.59 17.99 91 131662 10938 79601697
Ill-defined disorder 72.66 17.99 11 131742 65864 79546771
Blood pressure increased 70.92 17.99 152 131601 211208 79401427
Blood creatine phosphokinase increased 70.73 17.99 12 131741 66078 79546557
Wheezing 70.11 17.99 54 131699 116610 79496025
Tumour marker abnormal 70.09 17.99 24 131729 270 79612365
Agitation 69.62 17.99 39 131714 99676 79512959
Dry mouth 69.42 17.99 309 131444 87710 79524925
Plasma cell myeloma 68.68 17.99 5 131748 53254 79559381
Neoplasm recurrence 67.72 17.99 56 131697 4158 79608477
Suicidal ideation 67.52 17.99 21 131732 76319 79536316
Anaemia 66.77 17.99 1069 130684 443946 79168689
Loss of consciousness 65.80 17.99 110 131643 167833 79444802
Musculoskeletal stiffness 65.50 17.99 118 131635 174890 79437745
Hallucination 65.15 17.99 30 131723 85715 79526920
Irritable bowel syndrome 65.09 17.99 12 131741 62229 79550406
Oropharyngeal pain 64.89 17.99 354 131399 108999 79503636
Incorrect dose administered 64.42 17.99 23 131730 76607 79536028
Sedation 63.81 17.99 6 131747 51889 79560746
Discomfort 63.74 17.99 68 131685 125549 79487086
Myelosuppression 63.67 17.99 178 131575 40118 79572517
Hypokalaemia 63.52 17.99 87 131666 143953 79468682
Orthostatic hypotension 62.82 17.99 9 131744 56155 79556480
Aggression 62.37 17.99 6 131747 50952 79561683
Dry eye 62.20 17.99 167 131586 36764 79575871
Adverse event 62.13 17.99 12 131741 60202 79552433
Dizziness 62.04 17.99 1217 130536 525224 79087411
Type 2 diabetes mellitus 61.96 17.99 10 131743 57112 79555523
Rhinorrhoea 61.45 17.99 269 131484 75805 79536830
Abdominal discomfort 61.42 17.99 659 131094 250068 79362567
Carbohydrate antigen 27.29 increased 60.39 17.99 15 131738 45 79612590
Insomnia 60.34 17.99 645 131108 244525 79368110
Unresponsive to stimuli 59.99 17.99 10 131743 55778 79556857
Urticaria 59.82 17.99 136 131617 185065 79427570
PIK3CA-activated mutation 59.81 17.99 26 131727 577 79612058
Hypoxia 59.27 17.99 50 131703 103193 79509442
Dysarthria 59.10 17.99 19 131734 67603 79545032
Hypoacusis 58.71 17.99 144 131609 30006 79582629
Angina pectoris 58.54 17.99 8 131745 51724 79560911
Injection site reaction 58.51 17.99 10 131743 54775 79557860
Cytomegalovirus infection 58.00 17.99 3 131750 42641 79569994
Febrile neutropenia 57.88 17.99 192 131561 230807 79381828
Injection site pruritus 57.43 17.99 3 131750 42280 79570355
Vomiting 57.02 17.99 1471 130282 664357 78948278
Altered state of consciousness 56.84 17.99 4 131749 43818 79568817
Fibromyalgia 56.37 17.99 18 131735 64322 79548313
Renal failure 56.07 17.99 159 131594 200809 79411826
Psychotic disorder 56.04 17.99 3 131750 41399 79571236
Musculoskeletal chest pain 55.54 17.99 125 131628 24639 79587996
Pulmonary hypertension 55.45 17.99 7 131746 48073 79564562
Respiratory distress 55.40 17.99 14 131739 58325 79554310
Metastases to lung 55.29 17.99 104 131649 18059 79594576
Body surface area increased 55.02 17.99 17 131736 134 79612501
Heart rate decreased 54.36 17.99 24 131729 70292 79542343
General physical health deterioration 54.14 17.99 252 131501 274986 79337649
Ventricular tachycardia 53.89 17.99 4 131749 41931 79570704
Cardiogenic shock 53.86 17.99 4 131749 41910 79570725
Melaena 53.40 17.99 17 131736 60873 79551762
Oedema 52.95 17.99 72 131681 119508 79493127
Product packaging difficult to open 52.85 17.99 13 131740 37 79612598
Inappropriate schedule of product administration 52.83 17.99 87 131666 133541 79479094
Blood cholesterol increased 52.57 17.99 37 131716 83683 79528952
Stevens-Johnson syndrome 52.51 17.99 3 131750 39163 79573472
Off label use 52.49 17.99 1122 130631 906093 78706542
Rash maculo-papular 52.22 17.99 14 131739 56064 79556571
Drug dependence 52.08 17.99 4 131749 40765 79571870
Appetite disorder 51.87 17.99 64 131689 7675 79604960
Abdominal pain 51.71 17.99 404 131349 389165 79223470
Pyrexia 51.61 17.99 800 130953 677909 78934726
Flushing 51.60 17.99 42 131711 88226 79524409
Therapeutic response decreased 51.39 17.99 23 131730 66830 79545805
Drug ineffective for unapproved indication 51.23 17.99 11 131742 51227 79561408
Hair growth abnormal 51.12 17.99 40 131713 2744 79609891
Leukocytosis 50.92 17.99 6 131747 43449 79569186
Pancreatitis 50.55 17.99 25 131728 68550 79544085
Hypoaesthesia 49.92 17.99 484 131269 178868 79433767
Erythema 49.71 17.99 195 131558 223095 79389540
Skin exfoliation 49.28 17.99 201 131552 54899 79557736
Therapy non-responder 49.06 17.99 48 131705 92257 79520378
Hepatic lesion 49.00 17.99 59 131694 6900 79605735
Blood pressure fluctuation 48.71 17.99 25 131728 67120 79545515
Mental status changes 48.47 17.99 25 131728 66934 79545701
Feeling cold 48.47 17.99 130 131623 28599 79584036
Adverse drug reaction 47.75 17.99 25 131728 66367 79546268
Hepatic enzyme increased 47.68 17.99 149 131604 182461 79430174
Body surface area decreased 47.59 17.99 12 131741 39 79612596
Eating disorder 47.01 17.99 105 131648 20592 79592043
Product dispensing error 46.82 17.99 81 131672 13182 79599453
Unevaluable event 46.18 17.99 17 131736 55568 79557067
Rhabdomyolysis 45.76 17.99 62 131691 103069 79509566
Spinal pain 45.45 17.99 87 131666 15305 79597330
Sleep apnoea syndrome 45.43 17.99 4 131749 36474 79576161
Circulatory collapse 44.64 17.99 5 131748 37663 79574972
Bursitis 44.45 17.99 4 131749 35840 79576795
Nail growth abnormal 44.41 17.99 20 131733 484 79612151
Feeling abnormal 43.51 17.99 428 131325 158771 79453864
Osteoarthritis 43.47 17.99 48 131705 87261 79525374
Trichorrhexis 43.41 17.99 23 131730 800 79611835
Carcinoembryonic antigen increased 43.32 17.99 33 131720 2176 79610459
Upper gastrointestinal haemorrhage 43.22 17.99 8 131745 41372 79571263
Hypomagnesaemia 43.14 17.99 12 131741 46899 79565736
Drug level increased 42.87 17.99 7 131746 39644 79572991
Drug eruption 42.78 17.99 10 131743 43925 79568710
Drug withdrawal syndrome 42.72 17.99 4 131749 34714 79577921
Arrhythmia 42.71 17.99 24 131729 61248 79551387
Adnexa uteri mass 42.41 17.99 18 131735 376 79612259
Shock 42.23 17.99 10 131743 43538 79569097
Pallor 42.12 17.99 15 131738 50047 79562588
Proteinuria 42.06 17.99 3 131750 32499 79580136
Product quality issue 41.52 17.99 4 131749 33936 79578699
Tachypnoea 41.37 17.99 3 131750 32060 79580575
Heart rate increased 41.16 17.99 86 131667 120638 79491997
Cerebral haemorrhage 41.06 17.99 22 131731 57651 79554984
Obesity 40.79 17.99 5 131748 35120 79577515
Accidental exposure to product 40.22 17.99 3 131750 31319 79581316
Haematoma 40.05 17.99 18 131735 52177 79560458
Injection site swelling 39.86 17.99 14 131739 47118 79565517
Anaphylactic shock 39.72 17.99 6 131747 35990 79576645
Night sweats 39.65 17.99 181 131572 51914 79560721
Diabetic ketoacidosis 39.27 17.99 5 131748 34117 79578518
Acute respiratory failure 39.15 17.99 25 131728 59516 79553119
Emotional distress 39.11 17.99 9 131744 39960 79572675
Neutrophil count abnormal 39.09 17.99 38 131715 3488 79609147
Sinus tachycardia 38.84 17.99 7 131746 36901 79575734
Tremor 38.18 17.99 148 131605 169935 79442700
Prescribed overdose 38.14 17.99 8 131745 37875 79574760
Incorrect route of product administration 38.14 17.99 6 131747 34923 79577712
Abnormal behaviour 38.13 17.99 7 131746 36414 79576221
Knee arthroplasty 38.06 17.99 12 131741 43236 79569399
Nasal discomfort 37.81 17.99 46 131707 5437 79607198
Pulmonary thrombosis 37.43 17.99 70 131683 12101 79600534
Acute respiratory distress syndrome 37.42 17.99 13 131740 44054 79568581
Prescribed underdose 37.41 17.99 3 131750 29511 79583124
Pruritus 37.29 17.99 884 130869 393764 79218871
Dyskinesia 36.68 17.99 14 131739 44759 79567876
Urine odour abnormal 35.95 17.99 48 131705 6225 79606410
Chest pain 35.93 17.99 296 131457 282008 79330627
Pseudocirrhosis 35.86 17.99 19 131734 661 79611974
Blood pressure diastolic decreased 35.83 17.99 4 131749 30212 79582423
Electrocardiogram QT prolonged 35.58 17.99 59 131694 90327 79522308
Hypervolaemia 35.56 17.99 13 131740 42677 79569958
Coagulopathy 35.45 17.99 8 131745 35998 79576637
Basal cell carcinoma 35.43 17.99 9 131744 37366 79575269
Inflammation 35.25 17.99 63 131690 93690 79518945
Injection site haemorrhage 34.86 17.99 3 131750 27867 79584768
Malignant pleural effusion 34.83 17.99 35 131718 3345 79609290
Blood pressure decreased 34.63 17.99 70 131683 99396 79513239
Respiratory depression 34.49 17.99 3 131750 27627 79585008
Hemiparesis 34.22 17.99 7 131746 33726 79578909
Hair disorder 34.10 17.99 22 131731 1110 79611525
Staphylococcal infection 33.74 17.99 28 131725 58267 79554368
Ventricular fibrillation 33.71 17.99 6 131747 31920 79580715
Injection site bruising 33.29 17.99 13 131740 40989 79571646
Withdrawal syndrome 33.29 17.99 3 131750 26851 79585784
Obstructive airways disorder 33.03 17.99 6 131747 31453 79581182
Liver injury 33.01 17.99 27 131726 56587 79556048
Body temperature increased 31.54 17.99 17 131736 44403 79568232
Toothache 31.33 17.99 88 131665 19882 79592753
Thrombosis 31.26 17.99 242 131511 83858 79528777
Tubulointerstitial nephritis 31.25 17.99 12 131741 38223 79574412
Myocardial ischaemia 31.24 17.99 3 131750 25516 79587119
Wrong technique in product usage process 31.19 17.99 46 131707 73829 79538806
Palpitations 31.17 17.99 106 131647 126504 79486131
Pancreatitis acute 31.04 17.99 22 131731 49582 79563053
Disorientation 30.71 17.99 35 131718 62741 79549894
Urinary retention 30.61 17.99 29 131724 56601 79556034
Pleural neoplasm 30.52 17.99 14 131739 354 79612281
Metastases to bladder 30.52 17.99 13 131740 274 79612361
Chronic kidney disease 30.13 17.99 39 131714 66115 79546520
Alanine aminotransferase increased 30.11 17.99 152 131601 162418 79450217
Weight decreased 30.07 17.99 784 130969 354414 79258221
Increased appetite 29.75 17.99 63 131690 11915 79600720
Faeces soft 29.60 17.99 51 131702 8272 79604363
Ovarian disorder 29.57 17.99 15 131738 476 79612159
Prehypertension 29.55 17.99 7 131746 16 79612619
Hyperglycaemia 29.50 17.99 44 131709 70291 79542344
Breast cancer recurrent 29.17 17.99 30 131723 2947 79609688
Treatment noncompliance 29.16 17.99 26 131727 52242 79560393
Granulocyte count decreased 29.00 17.99 24 131729 1784 79610851
Body height decreased 28.48 17.99 51 131702 8529 79604106
Renal tubular necrosis 28.03 17.99 4 131749 25035 79587600
Haemorrhage intracranial 27.49 17.99 5 131748 26188 79586447
Poor quality product administered 27.47 17.99 32 131721 3613 79609022
Hallucination, visual 27.20 17.99 10 131743 32719 79579916
Drug-induced liver injury 27.11 17.99 42 131711 66075 79546560
Haematotoxicity 26.96 17.99 71 131682 15448 79597187
Neurotoxicity 26.92 17.99 10 131743 32508 79580127
Bone cancer 26.77 17.99 24 131729 1988 79610647
Deep vein thrombosis 26.63 17.99 106 131647 120813 79491822
Vulvovaginal dryness 26.61 17.99 25 131728 2199 79610436
Foot deformity 26.59 17.99 4 131749 24070 79588565
Chronic obstructive pulmonary disease 26.54 17.99 64 131689 85355 79527280
Hip arthroplasty 26.40 17.99 13 131740 35743 79576892
Liver function test abnormal 26.39 17.99 41 131712 64434 79548201
Face oedema 26.24 17.99 7 131746 28129 79584506
Transient ischaemic attack 26.20 17.99 29 131724 52666 79559969
Haematochezia 26.19 17.99 67 131686 87578 79525057
Aphthous ulcer 26.08 17.99 74 131679 16815 79595820
Myelodysplastic syndrome 25.63 17.99 9 131744 30292 79582343
Skin ulcer 25.62 17.99 31 131722 54119 79558516
Labelled drug-drug interaction medication error 25.56 17.99 7 131746 27643 79584992
Bronchospasm 25.55 17.99 5 131748 24854 79587781
Headache 25.48 17.99 1322 130431 652450 78960185
Subdural haematoma 25.47 17.99 10 131743 31424 79581211
Rectal haemorrhage 25.46 17.99 55 131698 76245 79536390
Pleural effusion 25.22 17.99 358 131395 144904 79467731
Emotional disorder 25.18 17.99 66 131687 14321 79598314
Device malfunction 25.03 17.99 3 131750 21445 79591190
Osteonecrosis 25.02 17.99 10 131743 31085 79581550
Clostridium difficile colitis 24.98 17.99 11 131742 32272 79580363
Parosmia 24.97 17.99 43 131710 6971 79605664
Restlessness 24.90 17.99 24 131729 46468 79566167
Therapeutic response unexpected 24.81 17.99 81 131672 19865 79592770
Red blood cell count abnormal 24.80 17.99 20 131733 1433 79611202
Diabetes mellitus inadequate control 24.69 17.99 5 131748 24259 79588376
Hypersomnia 24.56 17.99 89 131664 22997 79589638
Hepatic encephalopathy 24.54 17.99 5 131748 24161 79588474
Blood triglycerides increased 24.42 17.99 3 131750 21037 79591598
Nasopharyngitis 24.35 17.99 570 131183 253311 79359324
Mastectomy 24.35 17.99 18 131735 1134 79611501
Product use complaint 24.29 17.99 25 131728 2458 79610177
Accidental overdose 24.18 17.99 18 131735 39563 79573072
Diabetes mellitus 24.15 17.99 59 131694 78331 79534304
Abdominal pain upper 24.14 17.99 511 131242 223308 79389327
Toxic skin eruption 23.96 17.99 4 131749 22289 79590346
Sinusitis 23.95 17.99 207 131546 195294 79417341
Gastrointestinal disorder 23.94 17.99 112 131641 122093 79490542
Lip pain 23.73 17.99 23 131730 2104 79610531
Tongue blistering 23.57 17.99 20 131733 1539 79611096
Haemoptysis 23.51 17.99 35 131718 55964 79556671
Nephropathy toxic 23.48 17.99 3 131750 20416 79592219
Muscle twitching 23.40 17.99 6 131747 24758 79587877
Metastases to retroperitoneum 23.34 17.99 12 131741 392 79612243
Grip strength decreased 23.33 17.99 4 131749 21865 79590770
Joint range of motion decreased 23.25 17.99 13 131740 33269 79579366
Hepatitis 23.23 17.99 35 131718 55692 79556943
Paraesthesia 23.23 17.99 415 131338 175908 79436727
Epilepsy 23.19 17.99 20 131733 40840 79571795
Muscle spasms 22.93 17.99 411 131342 174319 79438316
Cerebral infarction 22.86 17.99 25 131728 45651 79566984
Metastases to lymph nodes 22.78 17.99 52 131701 10345 79602290
Tongue discomfort 22.74 17.99 24 131729 2429 79610206
Noninfective gingivitis 22.73 17.99 20 131733 1616 79611019
Infusion site coldness 22.71 17.99 10 131743 229 79612406
Peritonitis 22.58 17.99 9 131744 28027 79584608
Eructation 22.19 17.99 53 131700 10856 79601779
Agranulocytosis 22.14 17.99 25 131728 45005 79567630
Cyanosis 22.13 17.99 7 131746 25175 79587460
Dental discomfort 22.12 17.99 12 131741 438 79612197
Radiation injury 22.05 17.99 15 131738 828 79611807
Cholelithiasis 22.03 17.99 33 131720 52631 79560004
Ataxia 21.94 17.99 7 131746 25032 79587603
Aphasia 21.85 17.99 27 131726 46705 79565930
Joint neoplasm 21.84 17.99 7 131746 63 79612572
Nail discolouration 21.83 17.99 26 131727 3005 79609630
Neuroendocrine breast tumour 21.74 17.99 6 131747 30 79612605
Splenomegaly 21.70 17.99 4 131749 20750 79591885
Metastases to eye 21.65 17.99 10 131743 257 79612378
Hallucination, auditory 21.61 17.99 4 131749 20689 79591946
Product packaging issue 21.11 17.99 17 131736 1216 79611419
Gingival bleeding 21.06 17.99 67 131686 16209 79596426
Atrial flutter 20.90 17.99 5 131748 21620 79591015
Hypothyroidism 20.80 17.99 34 131719 52358 79560277
Nail avulsion 20.75 17.99 8 131745 129 79612506
Hyperaesthesia teeth 20.66 17.99 20 131733 1826 79610809
Oral herpes 20.60 17.99 95 131658 27359 79585276
Tooth disorder 20.60 17.99 92 131661 26141 79586494
Dialysis 20.55 17.99 3 131750 18459 79594176
Cardiomegaly 20.36 17.99 9 131744 26343 79586292
Inappropriate antidiuretic hormone secretion 20.30 17.99 9 131744 26304 79586331
Electrolyte imbalance 20.25 17.99 13 131740 30868 79581767
Mania 20.25 17.99 3 131750 18257 79594378
Feeding disorder 20.21 17.99 66 131687 16188 79596447
Acute coronary syndrome 20.20 17.99 5 131748 21128 79591507
Metastases to spine 20.19 17.99 30 131723 4294 79608341
Ileus 20.17 17.99 9 131744 26202 79586433
Metastases to kidney 20.00 17.99 12 131741 532 79612103
Soft tissue neoplasm 19.96 17.99 7 131746 85 79612550
Bacteraemia 19.96 17.99 15 131738 32809 79579826
Pulmonary arterial hypertension 19.93 17.99 11 131742 28355 79584280
Joint effusion 19.88 17.99 3 131750 18011 79594624
Skin sensitisation 19.81 17.99 15 131738 980 79611655
Neutropenic sepsis 19.74 17.99 10 131743 27054 79585581
Hypertensive crisis 19.69 17.99 5 131748 20765 79591870
Bone lesion 19.41 17.99 35 131718 5884 79606751
Hypovolaemia 19.40 17.99 3 131750 17688 79594947
Hypogeusia 19.27 17.99 19 131734 1775 79610860
Metastases to spinal cord 19.13 17.99 6 131747 50 79612585
Breast cancer 19.12 17.99 108 131645 33673 79578962
Acute myeloid leukaemia 18.93 17.99 14 131739 30871 79581764
Haematemesis 18.86 17.99 36 131717 52228 79560407
Aspiration 18.83 17.99 5 131748 20153 79592482
Foreign body in throat 18.74 17.99 11 131742 468 79612167
Metastases to the mediastinum 18.73 17.99 12 131741 598 79612037
Tumour pain 18.71 17.99 21 131732 2278 79610357
Post procedural complication 18.63 17.99 8 131745 23821 79588814
Tumour marker decreased 18.62 17.99 6 131747 55 79612580
Supraventricular tachycardia 18.54 17.99 6 131747 21264 79591371
Tongue disorder 18.52 17.99 58 131695 13917 79598718
Joint dislocation 18.29 17.99 3 131750 16936 79595699
Gamma-glutamyltransferase decreased 18.21 17.99 10 131743 374 79612261
Psychomotor hyperactivity 18.16 17.99 3 131750 16846 79595789
Uveitis 18.13 17.99 3 131750 16827 79595808
Acute cutaneous lupus erythematosus 18.02 17.99 10 131743 382 79612253

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EF01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Cyclin-dependent kinase (CDK) inhibitors
FDA MoA N0000175082 Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:82665 EC 2.7.11.22 (cyclin-dependent kinase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hormone receptor positive malignant neoplasm of breast indication 417181009
Human epidermal growth factor 2 negative carcinoma of breast indication 431396003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.03 Basic
pKa2 7.08 Basic
pKa3 5.81 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG IBRANCE PFIZER N207103 Feb. 3, 2015 RX CAPSULE ORAL 7456168 Jan. 16, 2023 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG IBRANCE PFIZER N212436 Nov. 1, 2019 RX TABLET ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG IBRANCE PFIZER N212436 Nov. 1, 2019 RX TABLET ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG IBRANCE PFIZER N212436 Nov. 1, 2019 RX TABLET ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG IBRANCE PFIZER N212436 Nov. 1, 2019 RX TABLET ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG IBRANCE PFIZER N212436 Nov. 1, 2019 RX TABLET ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG IBRANCE PFIZER N212436 Nov. 1, 2019 RX TABLET ORAL 7456168 Jan. 16, 2023 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cyclin-dependent kinase 6 Kinase INHIBITOR IC50 7.82 SCIENTIFIC LITERATURE DRUG LABEL
Cyclin-dependent kinase 4 Kinase INHIBITOR IC50 7.96 SCIENTIFIC LITERATURE DRUG LABEL
AP2-associated protein kinase 1 Kinase Kd 5.38 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 5 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 4.58 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 6.56 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.56 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.54 CHEMBL
Cyclin-dependent kinase 9 Kinase IC50 6.10 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.90 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.31 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.90 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 5.25 CHEMBL
Tyrosine-protein kinase JAK3 Kinase IC50 7.20 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 4.80 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 4.55 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 5.76 CHEMBL
Cyclin-dependent kinase 4/cyclin D1 Kinase IC50 8.70 CHEMBL
CDK2/Cyclin A Kinase IC50 6.64 CHEMBL
CDK6/cyclin D1 Kinase IC50 8.42 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Kinase Kd 6.68 CHEMBL
Uncharacterized protein FLJ45252 Unclassified Kd 4.56 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase INHIBITOR IC50 5.10 SCIENTIFIC LITERATURE
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase INHIBITOR IC50 5.70 SCIENTIFIC LITERATURE
Serine/threonine-protein kinase D3 Kinase Kd 4.79 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase IC50 5.46 CHEMBL

External reference:

IDSource
G9ZF61LE7G UNII
D10372 KEGG_DRUG
4034136 VUID
N0000191426 NUI
827022-33-3 SECONDARY_CAS_RN
4034136 VANDF
C3853822 UMLSCUI
CHEBI:85993 CHEBI
LQQ PDB_CHEM_ID
CHEMBL189963 ChEMBL_ID
5330286 PUBCHEM_CID
DB09073 DRUGBANK_ID
CHEMBL2364621 ChEMBL_ID
9802 INN_ID
C500026 MESH_SUPPLEMENTAL_RECORD_UI
7380 IUPHAR_LIGAND_ID
1601374 RXNORM
232484 MMSL
30872 MMSL
d08342 MMSL
015881 NDDF
715958001 SNOMEDCT_US
763549001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0187 CAPSULE 75 mg ORAL NDA 29 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0187 CAPSULE 75 mg ORAL NDA 29 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0188 CAPSULE 100 mg ORAL NDA 29 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0188 CAPSULE 100 mg ORAL NDA 29 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0189 CAPSULE 125 mg ORAL NDA 29 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0189 CAPSULE 125 mg ORAL NDA 29 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0284 TABLET, FILM COATED 75 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0284 TABLET, FILM COATED 75 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0486 TABLET, FILM COATED 100 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0486 TABLET, FILM COATED 100 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0688 TABLET, FILM COATED 125 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 0069-0688 TABLET, FILM COATED 125 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-187 CAPSULE 75 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-187 CAPSULE 75 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-188 CAPSULE 100 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-188 CAPSULE 100 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-189 CAPSULE 125 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-189 CAPSULE 125 mg ORAL NDA 33 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-284 TABLET, FILM COATED 75 mg ORAL NDA 32 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-284 TABLET, FILM COATED 75 mg ORAL NDA 32 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-486 TABLET, FILM COATED 100 mg ORAL NDA 32 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-486 TABLET, FILM COATED 100 mg ORAL NDA 32 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-688 TABLET, FILM COATED 125 mg ORAL NDA 32 sections
Ibrance HUMAN PRESCRIPTION DRUG LABEL 1 63539-688 TABLET, FILM COATED 125 mg ORAL NDA 32 sections